Hydroxypropyl Beta-Cyclodextrin Purification for Chronic CNS Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydroxypropyl beta-cyclodextrin compositions used for treating Niemann-Pick disease contain impurities like propylene glycol, unsubstituted beta-cyclodextrin molecules, and bacterial endotoxin, making them unsuitable for chronic intrathecal or intracerebroventricular administration, and their complex mixtures lack precise compositional control, necessitating the development of higher purity and defined pharmaceutical compositions.
Innovation Solution
Development of a pharmaceutical composition comprising beta-cyclodextrin molecules with controlled hydroxypropyl substitution, reduced impurities, and specific ratios, suitable for intrathecal or intracerebroventricular administration, achieved through methods such as absorption chromatography and solvent precipitation, ensuring low levels of propylene glycol, endotoxin, and precise compositional control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxypropyl beta-cyclodextrin compositions are used for treating Niemann-Pick disease, then therapeutic benefits are achieved, but impurities like propylene glycol, unsubstituted beta-cyclodextrin molecules, and bacterial endotoxin make them unsuitable for chronic intrathecal or intracerebroventricular administration
Solution Approach 1:
The patent applies extraction by removing harmful impurities from the hydroxypropyl beta-cyclodextrin composition. Specifically, unsubstituted beta-cyclodextrin molecules are removed through controlled hydrolysis conditions, and the composition is purified to eliminate propylene glycol and bacterial endotoxins, thereby making the composition suitable for chronic intrathecal or intracerebroventricular administration
Solution Approach 2:
The patent applies parameter changes by precisely controlling the degree of hydroxypropyl substitution (DS) within specific ranges (0.5-2.0, preferably 0.8-1.5) and controlling the average molecular weight. These parameter specifications ensure therapeutic efficacy while minimizing impurity formation and enabling safe chronic administration
2Reliability
If complex mixtures of hydroxypropyl beta-cyclodextrin are used, then therapeutic effects are observed, but precise compositional control is lacking
Solution Approach 1:
The patent applies parameter changes by defining precise compositional parameters: degree of hydroxypropyl substitution (DS) of 0.5-2.0, average molecular weight of 1000-5000 Da, and specific ratios of substituted to unsubstituted beta-cyclodextrin molecules (at least 80%, preferably at least 90%). These controlled parameters ensure both therapeutic efficacy and manufacturing precision
Solution Approach 2:
The patent applies local quality by specifying different compositional requirements for different aspects of the mixture. The composition allows a range of hydroxypropyl substitution degrees (0.5-2.0) to maintain therapeutic flexibility, while simultaneously enforcing precise control over impurity levels and molecular weight distribution to ensure safety and consistency
3Object-affected harmful factors
If higher purity compositions are developed, then safety for chronic administration is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by incorporating purification steps early in the manufacturing process. Controlled hydrolysis is performed before final formulation to remove unsubstituted beta-cyclodextrin molecules, and purification methods are applied to eliminate propylene glycol and endotoxins, thereby reducing impurity levels while managing manufacturing complexity through planned process integration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new composition provides therapeutic benefits for Niemann-Pick disease with improved safety and efficacy, allowing longer and more frequent dosing without adverse effects, as confirmed by gene expression profiling and clinical trial data.
Implementation Method 1
2-Hydroxypropyl-beta-cyclodextrins have been shown to alleviate excess cholesterol storage in NPC cells, consistent with a previous report of related cyclodextrins extracting cholesterol from the plasma membrane of cells
Implementation Method 2
achieved through methods such as absorption chromatography and solvent precipitation
Implementation Method 3
achieved through methods such as absorption chromatography and solvent precipitation
Data Source
AI summary
This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.